A Study to Evaluate the Safety, PK/PD of OriCAR-017 in Subjects With RR/MM - RIGEL Study
Phase 1
81
about 4 years
18–75
1 site in GA
What this study is about
Researchers are testing a treatment called OriCAR-017 for people with relapsed or refractory multiple myeloma. The trial will evaluate how safe and effective this treatment is.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take OriCAR-017
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Dose-limiting toxicity (DLT), Maximum tolerated dose (MTD) of OriCAR-017 US-P1
Secondary: Assessment of Disease Control Rate (DCR), Assessment of Duration of Response (DOR) of treatment in patients with RR/MM, Assessment of Overall Response Rate (ORR), Assessment of Overall Survival (OS) of treatment in patients with RR/MM, Evaluate PD parameters of OriCAR-017 in subjects with relapsed/refractory MM, Evaluate PK parameters of OriCAR-017 in subjects with relapsed/refractory MM, Progress-Free Survival (PFS) of treatment in patients with RR/MM
Cardiology / Heart, Oncology